Mankind Pharma lists at 20% premium, surges nearly 30% in debut trading
In debut trading, shares of the Manforce condom maker jumped as much as 29.62 per cent to touch a high of Rs 1,399.95 on BSE.
Stay updated with breaking news from Equity Strategy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In debut trading, shares of the Manforce condom maker jumped as much as 29.62 per cent to touch a high of Rs 1,399.95 on BSE.
Mankind Pharma IPO: The company is almost entirely focussed in India. The domestic market contributed 97.60 percent to the company's revenue from operations in FY22
The pharmaceutical and consumer health company’s over Rs 4,300 crore initial public offering (IPO) was open for subscription during April 25-27.
Given its healthy financial track record, domestic focus and extensive network, Mankind is likely to continue doing well, Hemang Jani of Motilal Oswal believes.
Some analysts blamed the ongoing crisis in the IT sector for the loss of interest in demat accounts. IT, which has historically been a key contributor to new account openings, is in throes of severe uncertainty, leading to large-scale downsizing and pay cuts